Roma Ehsan’s Post

A patient-led organization has just made an incredible breakthrough by repurposing a drug for a rare and deadly bleeding condition! Recently, a large clinical trial revealed that pomalidomide, originally developed for multiple myeloma, has proven effective in treating a life-threatening bleeding disorder called HHT (Hereditary Hemorrhagic Telangiectasia). This drug not only reduced bleeding events but also improved patients’ quality of life. Cure HHT brought together physicians, researchers, and patients to push this repurposing opportunity forward, showing the true power of patient-led organizations. At Every Cure, we aim to work closely with patient organizations to identify the most promising opportunities from our platform and ensure the necessary trials are conducted to benefit as many patients as possible. Because no one understands a rare disease better than those living with it. #raredisease #drugdevelopment #drugrepurposing #clinicaltrial

❗There is a pressing need for innovative pharmacological therapies to treat focal segmental glomerulosclerosis (FSGS), a rapidly progressing disease that frequently leads to end-stage renal disease, necessitating dialysis or a kidney transplant. 🧭Find out what the future holds for #FSGS and if your asset is positioned to make the greatest difference for these #patients.   Subscribed clients have the ability to: ✅Submit proprietary questions with insights that are exclusive to you ✅Partner with Spherix Global Insights market experts on key business questions, customized presentations and advisory services ✅Request ad-hoc data cuts and analyses 🌍Explore Spherix's FSGS services on our Client Portal. #focalsegmentalglomerulosclerosis

#Casestudy: Advancing Bioequivalence for Type-2 Diabetes and Weight management. Our latest research evaluates the bioequivalence of an injectable for Type 2 diabetes and weight management, crucial for ensuring consistent therapeutic outcomes. This research aims to ensure that new formulations match the safety and efficacy of existing therapies, offering patients reliable and effective treatment options. Read more about how these advancements contribute to better healthcare solutions and improved patient outcomes. #Type2Diabetes #WeightManagement #Bioequivalence #SyngeneResearch   

Digital Therapeutics (DTx) will redefine Chronic Disease Management. Under our "Leadership Series" Health Parliament is releasing the report 'The Promise & The Potential of Digital Therapeutics (DTx) for Digital Chronic Disease Management (DCDM)- A New Therapeutic Field'. We are also renaming the field of Chronic Disease Management (CDM) to Digital Chronic Disease Management (DCDM). The report explores how the integration of Digital Therapeutics into mainstream healthcare will expand the scope of treatable conditions and usher in a more patient-centric and precision-oriented era of medicine. To read more, download: https://lnkd.in/d4ShfHqr #health #healthcare #digitalhealth #publicpolicy #publichealth #digitaltherapeutics #chronicdisease #diseasemanagement

New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD

The hidden dangers of prediabetes   Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease.   https://lnkd.in/e4-geiYJ   The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.    As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.    For more information on the CELZ-201 trial, visit https://lnkd.in/eutVZQcX #creativemedical #celz #nasdaq #biotech

Dose optimization is a critical component in achieving the best therapeutic outcomes while minimizing the risk of adverse effects. By carefully adjusting the dosage based on individual patient factors—such as age, weight, renal and hepatic function, and genetic markers—healthcare providers can ensure that patients receive the most effective treatment at the lowest possible dose. This personalized approach not only enhances the efficacy of medications but also improves patient safety and reduces healthcare costs. Emphasizing dose optimization in clinical practice is key to advancing precision medicine and improving overall healthcare quality. #pharmacist #clinicalpharmacist #pharmacystudies

A new study shows that #finerenone, a medication for chronic kidney disease sold under the brand name Kerendia®(finerenone) HCP™ in the U.S., can significantly reduce the risk of worsening heart failure and cardiovascular death in specific patients. This offers a promising new treatment option for millions living with heart failure, particularly those with mildly reduced or preserved ejection fraction. The study, published in the New England Journal of Medicine (NEJM Group), underscores the need for continued research and innovation in this area. In order to receive FDA approval for use in these people with heart failure, Bayer, would need to apply to the agency for an expanded indication. Click here to read more: https://lnkd.in/egRf6uDm Read the study publication here: https://lnkd.in/edPKn6aB Find the clinical evidence for #Kerendia at DRUGDOCS® here: https://lnkd.in/eSjfwgBq

The American Diabetes Association returns for its 84th Annual Scientific Session on June 21st, bringing together researchers, healthcare professionals, and industry experts to delve into the latest advancements in diabetes research, treatment, and care.    With session themes focusing on therapeutics, management of acute or chronic complications, and behavioural medicine, it’s worth highlighting that the effectiveness of any treatment depends on its efficacy, safety, and patient adherence. Patient-centric integrated care approaches that enable real-time patient monitoring play a pivotal role in ensuring medication adherence and mitigating the risk and severity of complications associated with obesity, such as diabetes and hypertension.   Get in touch to arrange a meeting with Hakim Yadi Ph.D. OBE! Learn more about how Closed Loop Medicine is facilitating personalized disease management through our expanding portfolio of drug-plus-software combination products, to improve the effectiveness of medicines, such as GLP-1s, while reducing the impact of adverse effects:  https://shorturl.at/fMcea   #ADA2024 #TechBio #PrecisionCare

Have you used Ozempic, Wegovy, or Mounjaro? These medications for type 2 diabetes and weight loss have been associated with serious health issues such as intraoperative pulmonary aspiration, pancreatic cancer, severe or permanent stomach paralysis, gastroparesis, and other gastrointestinal injuries. If you or a loved one has experienced one of these conditions after using any of these medications, contact us for a free case review. Read our new blog to learn more: https://lnkd.in/eezKysmy